Scarica l'app Stockscreener
62.82
3.13%
-2.03
Pre-mercato:
62.84
0.02
+0.03%
Precedente Chiudi:
$64.85
Aprire:
$65.24
Volume 24 ore:
656.73K
Relative Volume:
1.06
Capitalizzazione di mercato:
$1.34B
Reddito:
$56.54M
Utile/perdita netta:
$-30.70M
Rapporto P/E:
-161.08
EPS:
-0.39
Flusso di cassa netto:
$-31.05M
1 W Prestazione:
+11.88%
1M Prestazione:
+34.12%
6M Prestazione:
+232.21%
1 anno Prestazione:
+430.57%
Intervallo 1D:
$62.00
$65.24
Intervallo di 1 settimana:
$54.52
$66.94
Portata 52W:
$10.14
$66.94
Cidara Therapeutics Inc Stock (CDTX) Company Profile
Nome
Cidara Therapeutics Inc
Settore
Industria
Telefono
858-752-6170
Indirizzo
6310 NANCY RIDGE DRIVE, SAN DIEGO, CA
Confronta CDTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CDTX
Cidara Therapeutics Inc
|
62.82 | 1.36B | 56.54M | -30.70M | -31.05M | -0.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Cidara Therapeutics Inc Stock (CDTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-18 | Ripresa | H.C. Wainwright | Buy |
| 2025-03-12 | Iniziato | Citizens JMP | Mkt Outperform |
| 2025-01-27 | Ripresa | Cantor Fitzgerald | Overweight |
| 2024-12-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-11-08 | Iniziato | Guggenheim | Buy |
| 2024-08-14 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2021-12-03 | Ripresa | H.C. Wainwright | Buy |
| 2021-09-22 | Aggiornamento | WBB Securities | Buy → Strong Buy |
| 2021-03-04 | Iniziato | Aegis Capital | Buy |
| 2019-09-04 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2018-07-26 | Iniziato | Citigroup | Buy |
| 2017-04-21 | Iniziato | Raymond James | Strong Buy |
| 2017-04-17 | Reiterato | H.C. Wainwright | Buy |
| 2017-04-12 | Iniziato | Ladenburg Thalmann | Buy |
| 2017-04-11 | Ripresa | Wedbush | Outperform |
| 2017-02-22 | Reiterato | H.C. Wainwright | Buy |
| 2017-02-22 | Aggiornamento | WBB Securities | Sell → Hold |
| 2016-12-21 | Ripresa | Leerink Partners | Outperform |
| 2016-12-19 | Iniziato | H.C. Wainwright | Buy |
| 2016-09-23 | Downgrade | WBB Securities | Hold → Sell |
| 2015-10-09 | Aggiornamento | WBB Securities | Sell → Hold |
| 2015-05-11 | Iniziato | Jefferies | Buy |
| 2015-05-11 | Iniziato | Leerink Partners | Outperform |
| 2015-05-11 | Iniziato | Needham | Buy |
| 2015-05-11 | Iniziato | Wedbush | Outperform |
| 2015-04-23 | Iniziato | WBB Securities | Sell |
Mostra tutto
Cidara Therapeutics Inc Borsa (CDTX) Ultime notizie
What analysts say about Cidara Therapeutics Inc. stockRapid market gains - PrintWeekIndia
Will Cidara Therapeutics Inc. stock benefit from interest rate changesFree Investment Community - jammulinksnews.com
What drives Cidara Therapeutics Inc. stock priceHigh-return market picks - Autocar Professional
Cidara Therapeutics to Report Second Quarter 2025 Financial - GlobeNewswire
Cidara Therapeutics Sets Q2 Earnings Date: Key Updates on DFC Immunotherapy Platform Expected - Stock Titan
Cidara Therapeutics to Report Second Quarter 2025 Financial Results and Host Quarterly Conference Call on August 7, 2025 - 富途牛牛
Is Cidara Therapeutics Inc. a good long term investmentMarket-beating returns - Autocar Professional
Cidara more than doubles on phase 2 flu preventative data - MSN
(CDTX) On The My Stocks Page - news.stocktradersdaily.com
ATAI Impresses, CDTX Navigates With Confidence, MTSR Builds Momentum, COGT Keeps Scaling The Summit… - RTTNews
Cidara Therapeutics Inc. Stock Analysis and ForecastFree Predictions - jammulinksnews.com
Growth or Bubble? Unpacking CDTX Stock Surge - timothysykes.com
Cidara Therapeutics stock hits 52-week high at 56.85 USD By Investing.com - Investing.com India
Cidara Therapeutics stock hits 52-week high at 56.85 USD - Investing.com
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Receives Average Rating of “Buy” from Brokerages - Defense World
What makes Cidara Therapeutics Inc. stock price move sharplyWatchlist Winner Update - Newser
Why Cidara Therapeutics Inc. stock attracts strong analyst attentionConsistent Growth Alert - newser.com
Finance Watch: A Mini-Surge In Follow-On Offerings Follows Positive Updates - insights.citeline.com
Segal Trials Contributes to Breakthrough Flu Prevention Study Led by Cidara Therapeutics - Business Wire
Cidara Therapeutics announces inclusion in the Russell 2000 and 3000 indexes - MSN
Cidara Therapeutics shares rise 1.47% premarket after granting inducement awards to new employees. - AInvest
Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - The Manila Times
Cidara Therapeutics shares fall 5.99% after-hours following inducement grants announcement. - AInvest
Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains - TradingView
hVIVO reports positive results from Cidara’s Phase 2b influenza study By Investing.com - Investing.com Canada
(CDTX) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Phathom Pharmaceuticals shares rise 1.47% premarket after Cidara Therapeutics closes $402.5 million stock offering. - AInvest
Cidara Therapeutics prices upsized $350 milion stock offering at $44 - MSN
Cidara Therapeutics Prices $350 Million Public Offering - MarketScreener
Cidara Therapeutics (CDTX) Price Target Raised by RBC Capital | CDTX Stock News - GuruFocus
Cidara Therapeutics announces $250M public stock offering - MSN
Cidara stock surges as H.C. Wainwright raises price target on trial data By Investing.com - Investing.com South Africa
Cidara Therapeutics suspends ATM prospectus for common stock sales By Investing.com - Investing.com Nigeria
Cidara Therapeutics Stock Jumps After-Hours As Strong Flu Trial Data Outweighs $250M Share Offering - MSN
Form 424B5 Cidara Therapeutics, - StreetInsider
Cidara Therapeutics (CDTX) to Launch $250M Public Offering | CDT - GuruFocus
Cidara Therapeutics plans $250 million common stock offering By Investing.com - Investing.com Canada
Cidara Therapeutics Announces Plans for $250 Million Underwritten Public Offering of Common Stock - Quiver Quantitative
Cidara Therapeutics (CDTX) Price Target Boosted Following Positi - GuruFocus
Cidara Therapeutics (CDTX) Receives Strong Buy Rating from WBB Securities | CDTX Stock News - GuruFocus
Cidara Therapeutics Stock Rises as Strategic Partnerships Strengthen Position - timothysykes.com
Cidara Therapeutics Announces Positive Topline Results from its Phase 2b NAVIGATE Trial Evaluating CD388, a Non-Vaccine Preventative of Seasonal Influenza - The Manila Times
Cidara Therapeutics Announces Positive Topline Results From Its Phase 2B Navigate Trial - TradingView
Crude Oil Falls 1%; US Services PMI Declines In June - Benzinga
Cidara Therapeutics Approves Key Amendments at Annual Meeting - TipRanks
(CDTX) Proactive Strategies - news.stocktradersdaily.com
Cidara Therapeutics (CDTX) Receives Buy Rating from HC Wainwrigh - GuruFocus
Cidara Therapeutics Inc Azioni (CDTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.32%
1.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):